These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19715911)

  • 1. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation.
    González E; Andrés A; Polanco N; Hernández A; Morales E; Hernandez E; Huerta A; Ortuño T; Gutiérrez Martínez E; Praga M; Morales JM
    Transplant Proc; 2009; 41(6):2332-3. PubMed ID: 19715911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
    Pascual J; Fernández AM; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii38-41. PubMed ID: 16815857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion therapy to everolimus in renal transplant recipients: results after one year.
    Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience.
    Hsu KH; Chou NK; Tsai MK; Chi NH; Chen YS; Yu HY; Wang CH; Ko WJ; Tsao CI; Lee PH; Wang SS
    Transplant Proc; 2010 Apr; 42(3):934-7. PubMed ID: 20430208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
    Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M
    Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function.
    Fernández A; Marcén R; Galeano C; Caldés S; Amezquita Y; Villafruela J; Pascual J; Burgos J; Rodríguez-Mendiola N; Ortuño J
    Transplant Proc; 2009; 41(6):2345-7. PubMed ID: 19715915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
    Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.